Logo

Qiagen, Evotec Form RNAi Imaging Technology Partnership

Sep 13, 2004

NEW YORK, Sept. 13 (GenomeWeb News) - Qiagen said today that it has signed a deal to combine its TOM-amidites chemistry-based RNAi products with Evotec Technologies' imaging Opera platform.

 

According to Qiagen, the companies intend to publish scientific application notes that applications that can be more easily accomplished using the combination of the technologies. The first application note, "Ultra High-Throughput Gene Silencing for Rapid, Economical Functional Genomics Studies," will be published by Qiagen in the "near future," the company said.

 

Financial terms of the arrangement were not disclosed.

 

Breaking News
The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.